91����

91���� and Phase Inc. have received a National Science Foundation (NSF) STTR grant to advance a new generation of 3D-printed microfluidic devices that could help move the technologies from the research lab toward broader commercial and scientific use.

The project combines the expertise of College of Science Professor ’s group in extracellular vesicle (EV) biology, and that of College of Engineering and Computing Associate Professor ’s group in bioengineering and materials characterization, at 91���� with vision to create an end-to-end, automated microfluidic platform that brings together custom device design, scalable 3D-printed polydimethylsiloxane (PDMS) chip manufacturing, and automated fluid handling. Specifically, this project leverages the microfluidic EV platform jointly developed and published by the Veneziano and Hakami groups.

Microfluidic devices use tiny channels to control small amounts of fluid and recreate environments on a cellular scale. They model human biology more realistically than flat cell cultures, making them important for drug discovery, disease research, and toxicology. Microfluidics are especially timely as the FDA has announced plans to phase out some animal testing requirements and encourage more human-relevant methods. 

Today, producing complex PDMS microfluidic devices often requires cleanrooms, manual optimization, and repeated trial-and-error. The NSF-supported work is designed to reduce that bottleneck by using thermal and curing models to predict how PDMS will behave during printing, then optimize print parameters before a device is manufactured. 

“This partnership helps us move one step closer to a fully automated, scalable microfluidic platform,” said Jeff Schultz, principal investigator and co-founder of Phase, which is headquartered in Charlotte, North Carolina. “Our goal is to make microfluidic technology more reproducible and more accessible to researchers and companies working to develop better human-relevant models.”

George Mason researchers will help characterize the printed devices for dimensional accuracy, surface quality, batch-to-batch consistency, and biological function. The team will also test a device designed to study EV function. EVs are nanoparticles that are released by cells and play critical roles in intercellular communication. They have been shown to carry important regulatory functions in various human diseases, such as cancer, infectious disease, and neurological disorders, and are also highly advantageous for use in drug delivery.

“Being able to rapidly and cost‑effectively prototype and fabricate custom microfluidic devices will significantly enhance our capacity to design relevant microphysiological systems and will help broaden access to this technology to many research laboratories” said Veneziano.

“Our microfluidic device empowers researchers to conduct functional EV studies with ease and under physiologically relevant conditions. Through our partnership with Phase to 3D print the chips, we will be able to deliver more reliable, cost-effective, and commercially viable tools to the EV scientific community,” said Hakami, co-director of the Center for Infectious Disease Research at George Mason.

For Phase, the NSF grant builds on a growing base of support from federal and private sources. The company has already received more than $3.5 million in nondilutive funding, including support from the , the , the , NSF, and private-sector partners. Previous research partners include Harvard Medical School, Georgia Tech, and . 

By pairing George Mason’s biological and engineering strengths with �ʳ󲹲���’s manufacturing platform, the project is positioned to advance both scientific discovery and commercialization. The result could be a more reliable path for producing the microfluidic tools needed to support the next wave of biomedical research, organ-on-a-chip development, and human-centered bio-innovation.